Skip to content

Effect of Barbed Suture Fascia Closure on Incisional Hernia in Midline Laparotomy for Gynecological Diseases (BARBHER)

Effects of Barbed Suture Fascia Closure on Incisional Hernia in Midline Laparotomy for Gynecological Disease (BARBHER)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04643197
Acronym
BARBHER
Enrollment
174
Registered
2020-11-25
Start date
2020-12-01
Completion date
2023-05-31
Last updated
2020-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic Disease

Brief summary

Investigators will compare the incidence of incisional hernia in women who underwent midline laparotomy whose abdominal fascia was closed with barbed suture vs. conventional non-barbed suture.

Interventions

DEVICEBarbed PDS suture (STRATAFIX Symmetric PDS Plus)

STRATAFIX Symmetric PDS Plus is a barbed suture.

DEVICENon-barbed PDS suture (PDS Plus)

Non-barbed suture

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

2\*2 factorial design Primary randomization: Barbed suture vs. Non-barbed suture in fascia closure Secondary randomization: subcutaneous drain insertion vs. non-insertion The effect of secondary randomization is one of secondary objectives.

Eligibility

Sex/Gender
FEMALE
Age
19 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Anticipating midline laparotomy for gynecologic diseases * ECOG performance status 0 - 2

Exclusion criteria

* Previous or current abdominal incisional hernia * Pregnant * Previous radiation on abdomen area * Allergy to PDS or irgacare MP * Having disease affecting wound healing such as uncontrolled DM, autoimmune vasculitis, liver cirrhosis, coagulopathy * BMI \> 35 * Current or anticipated use of drugs affecting wound healing such as bevacizumab (with 4 week drug free period, bevacizumab user is eligible) * Abdominal midline laparotomy within 6 months * Surgery for infection control

Design outcomes

Primary

MeasureTime frameDescription
Cumulative incidence of incisional herniafrom surgery to 1 yearIncisional hernia till 1 year after surgery

Secondary

MeasureTime frameDescription
Cumulative incidence of surgical site infectionfrom surgery to 4weeks
Incidence of wound dehiscencepost-surgery 4weeks
Time-event curve of incisional herniafrom surgery to 1 year
Treatment related adverse eventfrom surgery to 1 year
NRSfrom surgery to postoperative 4 daypain captured by NRS in nursing record, 0-10, higher score means more pain
Brief Pain Inventory - Korean (BPI-K) scoreBaseline, postoperative day 2, 4Pain measured with BPI-K Specifically score (0-10 all domain, higher score mean worse outcome) in domain of worst pain, least pain, average pain, current pain, impact of pain in general activity, mood, work, relationship, ambulation, sleep and happiness

Contacts

Primary ContactKidong Kim
kidong.kim.md@gmail.com82 31 787 7262

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026